Pcv-2 Vaccine

Abstract

The present invention relates to a vaccine against porcine circovirus type 2 (PCV-)2 and a method for the manufacture of such a vaccine, for protecting piglets against PCV-2 infection. It has been found that a vaccine comprising at least 20 microgram/dose of ORF-2 protein of porcine circovirus type 2 (PCV-2 is capable of eliciting a protective immune response against PCV-2 (and thus against PMWS) even when they have a relatively high titer of MDA against PCV-2. A vaccine according to the invention may contain a recombinant ORF-2 protein, wherein said recombinant protein is preferably produced by way of expression from a baculovirus expression vector in insect cells, said baculovirus expression vector containing the PCV-2 ORF-2 gene sequence under control of a suitable promoter.

1 . A vaccine for Protecting piglets having maternally derived antibodies (MDA) against PCV-2, comprising at least 20 micrograms/dose of ORF-2 protein of porcine circovirus type 2 (PCV-2). 
     
     
         2 . The vaccine according to  claim 1 , comprising at least 50 micrograms/dose of ORF-2 protein of porcine circovirus type 2 (PCV-2) 
     
     
         3 . The vaccine according to  claim 1 , wherein the ORF-2 protein is a recombinant protein. 
     
     
         4 . The vaccine according to  claim 1 , wherein the ORF-2 protein is produced by way of expression from a baculovirus expression vector in insect cells, said baculovirus expression vector containing the PCV-2 ORF-2 gene sequence under control of a suitable promoter. 
     
     
         5 . The vaccine according to  claim 4 , wherein the promoter is the p10 promoter. 
     
     
         6 . The vaccine according to any of the preceding claims  claim 1 , further comprising a suitable adjuvant. 
     
     
         7 . The vaccine according to  claim 6 , wherein the adjuvant is an oil in water emulsion. 
     
     
         8 . The vaccine according to  claim 6 , wherein the adjuvant contains vitamin E. 
     
     
         9 . A method for the protection of piglets that are PCV-2 MDA positive against PCV-2 infection, comprising administering a vaccine according to  claim 1  comprising at least 20 micrograms/dose of ORF-2 protein of porcine circovirus type 2 (PCV-2).